The New FDA Commissioner

By SAURABH JHA, MD That the appointment of Scott Gottlieb to head the FDA has elicited a decidedly mixed response is a good thing. I fear consensus as much as the late Christopher Hitchens loved dissent which, he believed, was an indicator of a healthy democracy, which means that rather than facing the morgue, the US might be going through her healthiest days in these times. Gottlieb has served on the boards of industry, and earned a nifty pocket money doing so. Detractors argue that he’s unfit to head the FDA because of his financial conflict of interest (FCOI). I will not revisit the arguments for and against physician’s FCOI with industry, because all arguments for and against have been made, and it’s unlikely that anyone’s mind will change with new evidence or new arguments. Suffice it to say that both sides have plausible arguments, and we’ll never know the truth, because to know the real impact of physician’s FCOI with industry we need parallel universes with everything held constant, except the degree of physician ties with industry, and measure the net benefits to society in terms of morbidity, mortality, drug prices, and innovations. Further, Gottlieb’s FCOI with industry can work in opposing ways. He may, indeed, favor certain industries because of his intimacy with them, rather than what they do, which will lead to regulatory capture. But he may not. In fact, he may be so aware that his FCOI will invite disproportionate scrutiny that he will overcom...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Economics Source Type: blogs